ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Tyra Biosciences, Inc. Logo
Biotech developing precision FGFR medicines for cancer and genetic disorders.
United States of America
TYRA
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY
UNION KOREA PHARM CO.,Ltd Logo
Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.
South Korea
080720
uniQure N.V. Logo
Developing AAV-based gene therapies for rare liver and central nervous system disorders.
United States of America
QURE
UNITED THERAPEUTICS Corp Logo
Develops therapies for chronic diseases and manufactures organs for transplantation.
United States of America
UTHR
Universe Pharmaceuticals INC Logo
Manufactures, markets, and distributes TCM derivative products and biomedical drugs.
United States of America
UPC
Univo Pharmaceuticals Ltd. Logo
Vertically integrated biopharma firm developing medical cannabis treatments with a focus on CNS.
Israel
UNVO-M

Talk to a Data Expert

Have a question? We'll get back to you promptly.